Minimal Residual Disease (MRD) Testing News and reporting on minimal residual disease testing. Dec 21, 2022 Natera Files Second Patent Infringement Suit Against NeoGenomics Subsidiary Inivata Dec 21, 2022 Guardant Health, Susan G. Komen Partner to Evaluate MRD Test in Breast Cancer Dec 15, 2022 Study Shows Value of Routine MRD Analysis Using Foresight's PhasED-Seq in Lymphoma Patients Premium Dec 13, 2022 Gilead's Yescarta Safe and Effective for CNS Lymphoma Patients, Pilot Study Shows Premium Dec 12, 2022 NeoGenomics Growing Evidence Base for Residual Disease Assay in Breast Cancer Premium Dec 11, 2022 Bristol Myers Squibb, 2seventybio's Abecma Shows Benefit in High-Risk Multiple Myeloma Patients Premium Nov 28, 2022 SeekIn Receives CE-IVD Mark for Cancer Recurrence Monitoring Test Nov 16, 2022 Liquid Biopsy Startup Haystack Oncology Raises $56M in Series A Round Aug 15, 2022 Personalis, BC Cancer Partner on Study of ctDNA MRD Tests for Colorectal, Pancreatic Cancers Aug 3, 2022 Exact Sciences Partners With West German Study Group to Validate MRD Test in Breast Cancer Aug 2, 2022 Guardant Health Receives Medicare Coverage for MRD Liquid Biopsy in Stage II and III Colon Cancer Jul 29, 2022 Stakeholders Urge Collaboration to Prove ctDNA as Regulatory Endpoint for Early Cancer Drugs Premium Jul 28, 2022 Adaptive Biotech's ClonoSeq Gets Expanded Medicare Coverage For B-Cell Lymphoma Jul 22, 2022 Lung Cancer MRD Study Bolsters Validity Evidence, Suggests Longitudinal Test Cutoff Premium Jul 21, 2022 Survey Shows Half of Doctors Consider MRD Status When Treating Multiple Myeloma Patients Premium Jun 8, 2022 New Data Suggests Liquid Biopsy Provides Early ID of Breast Cancer Patients Destined to Recur Premium Jun 7, 2022 Circulating Tumor DNA Utility in Post-Surgery Stage II Colon Cancer Cemented by New Data Premium May 6, 2022 Drugmakers Come Together Hoping to Formalize MRD as Surrogate Endpoint in AML Trials Apr 19, 2022 Genetron Health Nabs CE Mark for Blood Cancer Residual Disease Test Kit Mar 9, 2022 Natera Minimal Residual Disease Test Value Called Into Question by City of Hope CRC Patient Data Load More Breaking News Ratio Therapeutics Raises $20M in Series A Financing Guardant Health, AnHeart Tx to Develop Blood- and Tissue-Based CDx for NSCLC Drug Ellipses Pharma Cleared by FDA to Open Phase I/II AML Trial Survey Reveals Changing Genetic Testing Patterns, Persistent Disparities in Precision Oncology Amgen's Lumakras Sales Increased 58 Percent in Q4 2022 Coeptis Therapeutics, University of Pittsburgh Studying SNAP-CAR Therapy in HER2-Positive Cancers
